Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hormone Refractory Prostate Cancer: New Studies In Austria

29.03.2010
- Three clinical trials started at the Medical University of Vienna
- Commissioned by multinational pharmaceutical firms

The Medical University of Vienna has been commissioned by international pharmaceutical firms to conduct three clinical trials of the treatment of recurrent prostate tumors (hormone refractory prostate carcinomas). The new approaches comprise immunotherapy, hormone therapy and an augmented form of the current standard treatment with docetaxel.

Team leader Prof. Dr. Michael Krainer and his colleagues will concentrate primarily on tumors diagnosed late or those which recur after surgical interventions, and which do not (or no longer) respond to common treatments such as androgen deprivation.

IMMUNOTHERAPY
The team will investigate the use of the monoclonal antibody ipilimumab as part of the immunotherapeutic treatment. This antibody can cause the body's own immune system to react against cancer cells. Prof. Krainer said that "the use of ipilimumab rather than docetaxel has led to rather surprising successes during the past year in a small-scale trial. In three patients, a tumor that had been hard to treat became so small that it could be surgically removed. Since a small-scale trial of this nature only allows limited claims to be made about the drug, ipilimumab is now being investigated further in a larger study."
HORMONE THERAPY
A hormone treatment based on the drug MDV3100 is also being trialed by the team at the Medical University of Vienna. This is used as a second-line treatment after the initial treatment with docetaxel. MDV3100 is a substance that blocks the androgen receptor and thus offers a new approach to the prevention of hormone dependent tumor growth.
AUGMENTED STANDARD TREATMENT
In the past, Prof. Krainer and his team were able to show the efficacy of docetaxel versus other common chemotherapeutic drugs. The third trial at the Medical University of Vienna will test the combination of docetaxel with the tyrosine kinase inhibitor sunitinib. As part of the trial, the researchers will examine biomarkers in the patients' blood that will yield information about the progress of the treatment.
TOP QUALITY RESEARCH IN AUSTRIA
"We are delighted that multinational pharmaceutical companies find in Austria the optimal environment and competent partners for clinical trials and basic research", said Dr. René Siegl, Managing Director of the Austrian investment promotion company ABA - Invest in Austria. "This shows that the conditions at the location Austria are ideal". More than 15 percent of Austrian R&D expenditure comes from foreign commissions. With 2.73 percent of the GNP in 2009 being spent on research, Austria has closed the gap with other European countries at the forefront of innovation. The aim is a research quota of 4 percent by 2020. In future Austria will create even greater incentives for businesses to attract innovation centers and will further develop collaborative endeavors between the scientific and business worlds.

For further information please contact:

Hanni Grassauer
ABA - Invest in Austria
Opernring 3
1010 Wien, Austria
T +43 / 1 / 588 58 57
F +43 / 1 / 586 86 59
E h.grassauer@aba.gv.at
Mag. Marta Korinkova
PR-Assistentin & Office Managerin
PR&D - Public Relations für Forschung & Bildung
T +43 1 505 70 44
F +43 1 505 50 83
E korinkova@prd.at
Campus Vienna Biocenter 2
1030 Vienna, Austria

Marta Korinkova | PR&D
Further information:
http://www.investinaustria.at
http://www.prd.at

More articles from Life Sciences:

nachricht Cells communicate in a dynamic code
19.02.2018 | California Institute of Technology

nachricht Studying mitosis' structure to understand the inside of cancer cells
19.02.2018 | Biophysical Society

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Contacting the molecular world through graphene nanoribbons

19.02.2018 | Materials Sciences

When Proteins Shake Hands

19.02.2018 | Materials Sciences

Cells communicate in a dynamic code

19.02.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>